Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Cartesian Therapeutics, Inc. Director's Dealing 2022

Jan 18, 2022

33483_dirs_2022-01-18_8bcf571b-98c9-46c2-978e-9b9c884d10fb.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: SELECTA BIOSCIENCES INC (SELB)
CIK: 0001453687
Period of Report: 2022-01-14

Reporting Person: BARABE TIMOTHY C (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2022-01-14 Common Stock M 10000 $2.10 Acquired 200013 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2022-01-14 Stock Option (Right to Buy) $2.1 M 10000 Disposed 2029-06-13 Common Stock (10000.0) Direct

Footnotes

F1: This option is fully vested.